Should Cannabinoids Be Recommended to Patients With Neuropathic Pain?
Two expert physicians with opposing viewpoints debate the risks and benefits of using cannabinoids for treating neuropathic and chronic pain.
Two expert physicians with opposing viewpoints debate the risks and benefits of using cannabinoids for treating neuropathic and chronic pain.
Although studies have shown cannabis reduces pain and has opioid-sparing effects, a large-scale longitudinal clinical study on the effects of cannabis products on patients was needed.
This study looks at the perioperative management of cannabis use in patients who are undergoing surgery with anesthesia.
Maternal cannabis use during pregnancy is tied to higher risk for neurodevelopmental disorders in offspring.
Given public interest, CBD should be a public health priority to evaluate effects, safety, the authors say
The claimed their CBD products on their social media website and online store claiming that the products can be used to treat a variety of conditions and diseases including teething pain and earaches in infants, skin problems, autism, ADHD, Parkinson disease, and Alzheimer disease, among others.
There is insufficient evidence to support the use of medical cannabis or cannabis-related medications for the treatment of musculoskeletal and autoimmune disorders.
At Psych Congress 2018, Andrew Penn from the UCSF School of Nursing provides insight into the use of CBD in clinical practice.
There is limited evidence supporting the efficacy of cannabis for refractory chronic pain, including chronic neuropathic pain.
There are a number of challenges associated with the use of cannabidiol and hemp oils in pain management.